title: [Drug therapy of patients with recurrent glioblastoma: is there any evidence?].
abstract: SYSTEMIC THERAPY IN PATIENTS WITH RELAPSED GLIOBLASTOMA: For patients with relapsed GBM there is currently no standard systemic therapy.
  Wick et al. treated 64 patients with TMZ 150 mg/m(2), one week on, one week off and observed PFS-6 of 43.8%, and OAS of 8.4 months after the diagnosis of relapse. Strik et al. reported on 13 patients treated 5 days in a week and observed a PFS-6 of 39%, OAS of 7.8 months, Perry et al. reported on 50 mg/m(2).
  Vredenburgh et al. reported prospectively rapid symptomatic relief, PFS-6 of 46% and OAS of 8 months in 35 patients with relapsed GBM. The BRAIN study evaluated 167 patients with Avastin/Irinotecan vs. Avastin alone in patients with relapsed GBM, showing PFS-6 of 50 vs. 42% and OAS of 8.7 vs. 9.2 months.
  More than 40 drugs are currently investigated in patients with relapsed gliomas.
  Should be part of all interactions with a neuro-oncologist.
  
  
  CONCLUSIONS
  Thorough consideration of the individual patient's characteristics to evaluate the best fitted treatment is warranted, preferentially in the context of an interdisciplinary tumour board.
authors.affiliation: Konsiliarfach Innere Medizin mit Neuroonkologie, Landes-Nervenklinik Wagner-Jauregg, Linz, Österreich. josef.pichler@gespag.at
authors.forename: Josef
authors.initials: J
authors.lastname: Pichler
authors.forename: Christine
authors.initials: C
authors.lastname: Marosi
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D000068258:Bevacizumab; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005909:Glioblastoma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D010166:Palliative Care; D019233:Retreatment; D015996:Survival Rate; D000077204:Temozolomide
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018906:Antineoplastic Agents, Alkylating; D015507:Drugs, Investigational; D000068258:Bevacizumab; D003606:Dacarbazine; D000077204:Temozolomide